Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moderna, Inc. (MRNA) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance

Moderna, Inc.Trade
Invesco S&P 500 Momentum ETFTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs Invesco S&P 500 Momentum ETF — how do they compare? Moderna, Inc. trades at $60.45 (market cap $24.18B), while Invesco S&P 500 Momentum ETF trades at $151. The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.

MRNASPMO
Market Cap
$24.18B
Sector
HealthBroad Market / Factor
52-Week High
$81.80$161.66
52-Week Low
$22.36$107.84
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.

Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.

Invesco S&P 500 Momentum ETF

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA

About Invesco S&P 500 Momentum ETF

SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.

Read more on SPMO